Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K El-Shami

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Leukemia|June 20, 2008
Immunotherapy for myeloid leukemias: current status and future directionsK el-Shami, B D Smith
Immunology Letters|September 21, 2000
Antitumor vaccination using peptide based vaccinesL Eisenbach, E Bar-Haim, K El-Shami
European Journal of Immunology|October 30, 1999
MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitopeK el-Shami, B Tirosh, E Bar-Haim, et al.
Immunology Letters|November 30, 1999
Immunogenicity of H-2Kb-low affinity, high affinity, and covalently-bound peptides in anti-tumor vaccinationB Tirosh, K el-Shami, N Vaisman, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Leukemia|June 20, 2008
Immunotherapy for myeloid leukemias: current status and future directionsK el-Shami, B D Smith
Immunology Letters|September 21, 2000
Antitumor vaccination using peptide based vaccinesL Eisenbach, E Bar-Haim, K El-Shami
European Journal of Immunology|October 30, 1999
MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitopeK el-Shami, B Tirosh, E Bar-Haim, et al.
Immunology Letters|November 30, 1999
Immunogenicity of H-2Kb-low affinity, high affinity, and covalently-bound peptides in anti-tumor vaccinationB Tirosh, K el-Shami, N Vaisman, et al.
Pageof 1